Quest Diagnostics Inc. (DGX) announced today that the Company's Board of Directors declared a cash dividend of $0.66 per common share payable on April 20, 2022, to stockholders of record at the close of business on April 6, 2022.

This 6.5 percent dividend hike in 2022 follows a dividend hike of 10.7 percent to $0.62 per share in 2021. This also marks the 12th consecutive year of annualized dividend increases by the clinical lab results database provider.

A new annualized dividend rate of $2.64 per share yields 1.9% at a stock price of $140.52. Quest Diagnostics will pay shareholders a total annual dividend of $323 million if we include this new hike just announced.

Quest Diagnostics Incorporated is a provider of diagnostic information services. Quest Diagnostics ows the world's largest database of clinical lab results and the company's diagnostic insights reveal new avenues to identify and treat disease, inspire healthy behaviors and improve health care management. DGX's services are provided under the Quest Diagnostics brand, but it also provides services under other brands, including AmeriPath, Dermpath Diagnostics, Focus Diagnostics, Athena Diagnostics, ExamOne, Quanum and Care360.